Advanced SearchSearch Tips
A Strategy Using Photodynamic Therapy and Clofibric Acid to Treat Peritoneal Dissemination of Ovarian Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
A Strategy Using Photodynamic Therapy and Clofibric Acid to Treat Peritoneal Dissemination of Ovarian Cancer
Yokoyama, Yoshihito; Shigeto, Tatsuhiko; Miura, Rie; Kobayashi, Asami; Mizunuma, Makito; Yamauchi, Aisa; Futagami, Masayuki; Mizunuma, Hideki;
  PDF(new window)
Background: The current study examined the effectiveness of concurrent therapy using photodynamic therapy (PDT) and clofibric acid (CA) to treat peritoneal carcinomatosis resulting from ovarian cancer. Materials and Methods: Nude rats were used to create a model of peritoneal carcinomatosis resulting from ovarian cancer and the effectiveness of PDT with 5-aminolevulinic acid methyl ester hydrochloride (methyl-ALA-PDT) was determined. The survival time of rats receiving that therapy was compared to the survival time of a control group. Rats with peritoneal carcinomatosis resulting from ovarian cancer were divided into 3 groups: a group that received debulking surgery (DS) alone, a group that received DS+methyl-ALA-PDT, and a group that received DS+methyl-ALA-PDT+CA. The survival time of the 3 groups was compared. Protoporphyrin, a metabolite of methyl-ALA, produces a photochemical action when activated by light. The level of protoporphyrin (the concentration) that reached organs in the abdomen was measured with HPLC. Results: Rats receiving methyl-ALA-PDT had a significantly longer survival time compared to the controls. Rats with peritoneal carcinomatosis that received DS+methyl-ALA-PDT+CA had a significantly longer survival time compared to the rats that received DS alone. Some of the rats that received concurrent therapy survived for a prolonged period. Protoporphyrin was highly concentrated in peritoneal metastases, but only small amounts reached major organs in the abdomen. PDT was not found to result in necrosis in the intestines. Conclusions: The results indicated that concurrent therapy consisting of PDT with methyl-ALA and CA is effective at treating peritoneal carcinomatosis resulting from ovarian cancer without damaging organs.
Photodynamic therapy;clofibric acid;peritoneal carcinomatosis;ovarian cancer;5-aminolevulinic;
 Cited by
Akeson M, Zetterqvist BM, Dahllöf K, et al (2008). Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohortstudy of all patients in western Sweden with long-term follow-up. Acta ObstetGynecol Scand, 87, 1343-52. crossref(new window)

Casson AG (2009). Photofrin PDT for early stage esophageal cancer: a new standard of care? Photodiagnosis Photodyn Ther, 6, 155-6. crossref(new window)

Choi MC, Lee C, Kim SJ (2014). Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia:a systemic review. Photodiagnosis Photodyn Ther, 11, 479-80. crossref(new window)

del Carmen MG, Rizvi I, Chang Y, et al (2005). Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst, 97, 1516-24. crossref(new window)

Gallagher-Colombo SM, Miller J, Cengel KA, et al (2015). Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via multiple Mechanisms. Cancer Res, 75, 3118-26. crossref(new window)

Ikeda N, Usuda J, Kato H, et al (2011). New aspects of photodynamic therapy for central type early stage lung cancer. Lasers Surg Med, 43, 749-54. crossref(new window)

Kroep JR, Nortier JW (2012). The role of bevacizumab in advanced epithelial ovarian cancer. Curr Pharm Des, 18, 3775-83. crossref(new window)

Lee CK, Lord S, Grunewald T, et al (2015). Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol Oncol, 136, 18-24. crossref(new window)

Lucena SR, Salazar N, Gracia-Cazana T, et al (2015). Combined treatments with photodynamic therapy for non-melanoma skin cancer. Int J Mol Sci, 16, 25912-33. crossref(new window)

Li Z, Sun L, Lu Z, et al (2015). Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system. Int J Oncol, 47, 1070-6. crossref(new window)

Liu AH, Sun X, Wei XQ, et al (2013). Efficacy of multiple lowdose photodynamic TMPYP4 therapy on cervical cancer tumour growth in nude mice. Asian Pac J Cancer Prev, 14, 5371-4. crossref(new window)

Peng Q, Warloe T, Moan J, et al (2001). Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res, 61, 5824-32.

Rizvi I, Celli JP, Evans CL, et al (2010). Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res, 70, 9319-28. crossref(new window)

Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. crossref(new window)

Spinelli P, Dal Fante M, Mancini A (1992). Current role of laser and photodynamic therapy in gastrointestinal tumors and analysis of a 10-year experience. Semin Surg Oncol, 8, 204-13. crossref(new window)

Wakui M, Yokoyama Y, Wang H, et al (2010). Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers. J Cancer Res Clin Oncol, 136, 1143-50. crossref(new window)

Wang C, Chen X, Wu J, et al (2013). Low-dose arsenic trioxide enhances 5-aminolevulinic acid-induced PpIX accumulation and efficacy of photodynamic therapy in human glioma. J Photochem Photobiol B, 127, 61-7. crossref(new window)

Wei XQ, Ma HQ, Liu AH, et al (2013). Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells. Asian Pac J Cancer Prev, 14, 3023-8. crossref(new window)

Weiss A, Bonvin D, Berndsen RH, et al (2015). Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep, 5, 8990. crossref(new window)

Yokoyama Y, Xin B, Shigeto T, et al (2007). Clofibric acid, a peroxisome proliferator activated receptor a ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther, 6, 1379-86. crossref(new window)

Yokoyama Y, Hirakawa H, Wang H, et al (2012). Is omentectomy mandatory in the operation for ovarian cancer? Eur J Obstet Gynecol Reprod Biol, 164, 89-92. crossref(new window)

Yu J, Cao XF, Zheng Y, et al (2014). Anti-VEGF Therapy with Bevacizumab--limited cardiovascular toxicity. Asian Pac J Cancer Prev, 15, 10769-72.